The Rebound Effect: Patients Regain Weight Rapidly After Stopping GLP-1 Shots, Cambridge Study Finds

The medications are effective. There is no longer any doubt about that part. Semaglutide, the active ingredient in Ozempic and Wegovy, has been shown in clinical trials to cause 15–20% weight loss in patients who continue their treatment. That’s 37 to 50 pounds lost for a person weighing 250 pounds, which would be impressive for any kind of intervention. What happens when people stop is the issue, which a group of Cambridge medical students have now quantified more accurately than anyone has ever done.

The study, which was published in eClinicalMedicine on March 4, combined data from 48 studies to create a mathematical model of weight gain following the discontinuation of GLP-1 medication. The model was mainly based on six randomized controlled trials that tracked over 3,200 patients for up to 52 weeks after stopping medication. The pattern is steady and predictable: a quick initial regain that slows down over time, reaching about 60% of the initial weight loss by the one-year mark and expected to plateau at about 75%. This implies that a person who lost 20 pounds while taking the drug would ultimately maintain a weight loss of roughly 5 pounds over time. The fifteen that are left return.

“Drugs like Ozempic and Wegovy act like brakes on our appetite,” stated Brajan Budini, a Trinity College medical student and one of the study’s lead authors. “When people stop taking them, they are essentially taking their foot off the brake, and this can lead to rapid weight regain.” The metaphor accurately describes how these medications function and the reasons behind the strong rebound. GLP-1 receptor agonists alter the fundamental sensation of eating by slowing gastric emptying and suppressing hunger signals. These mechanisms reverse once the drug exits the body. Because there is less fat tissue, leptin levels decrease. The hunger hormone, ghrelin, increases. After being pharmacologically suppressed, the brain’s control over appetite reemerges. The body is reacting precisely as biology would predict; it is not malfunctioning.

The modeling of the deceleration curve is what makes the Cambridge findings especially helpful. Weight gain is not linear; it increases most quickly in the initial months following a cessation before progressively slowing down. The researchers predict a longer tapering process that eventually stabilizes, with the 60 percent figure at one year serving as a midpoint. Compared to what the early STEP-1 extension data indicated when semaglutide patients were monitored for just over a year, that plateau at 75 percent is actually a slightly more optimistic prediction. One of the real open questions the study raises is the possibility that 25% of the loss might persist even after stopping, but there are important disclaimers.

Body composition is the most uncomfortable of those cautions. According to research, lean mass, or muscle, may account for 40–60% of the weight lost during GLP-1 treatment as opposed to fat. This is concerning in and of itself because, especially in older patients, losing muscle slows metabolism and increases functional limitations. However, the Cambridge researchers discovered an even more disturbing version of the question: patients may have a worse fat-to-lean ratio than they had prior to beginning treatment if the weight that returns after stopping the medication is disproportionately fat rather than a proportionate mix of fat and muscle. “If the regained weight is disproportionately fat, individuals may ultimately be worse off than before in their fat-to-lean mass ratio,” said Budini. This is not resolved by the study; rather, it is identified as a crucial unanswered question that requires further investigation.

Another factor was revealed by a different Oxford study that was published in January 2026: individuals who stop taking GLP-1 medications gain weight four times more quickly than those who lose weight through behavioral programs like diet and exercise. The difference in speed is important. Rapid weight gain is typically disproportionately fat, and it tends to return to the abdomen in particular, where visceral fat accumulation carries the highest risk of cardiovascular disease.

Using data from 18 randomized controlled trials involving 3,771 patients, a simultaneous meta-analysis published in the NIH’s PMC database discovered that stopping GLP-1 therapy was linked to significant increases in waist circumference, systolic blood pressure, fasting blood glucose, and HbA1c—not just weight. Not only does the scale number decline, but the cardiovascular and metabolic picture also deteriorates. In particular, the rebound in systolic blood pressure for semaglutide was 7.09 mmHg as opposed to 1.56 mmHg for liraglutide. The researchers attributed this difference to semaglutide’s longer half-life and stronger central appetite suppression, which may cause a more noticeable counter-regulatory response when the medication is stopped.

The background for all of this is that about half of patients who begin taking these drugs quit within the first year, and by the end of the second year, three-quarters have done so. Cost is a significant factor, as are side effects like nausea, vomiting, and gastroparesis, as well as insurance coverage restrictions that make regular access extremely challenging for many patients. Together, the rebound research makes the case that GLP-1 medications should be viewed more like blood pressure medication and less like a course of antibiotics: maintenance therapy, possibly indefinite, with careful planning around any discontinuation. The research now identifies structured tapering protocols, behavioral interventions incorporated prior to cessation, and transparent metabolic monitoring following cessation as gaps in the actual writing of prescribing guidelines rather than as potential future developments.